Optimized Amorphous Nanoparticles: An Approach to Boost Solubility and Skin Permeability of Mometasone Furoate

The efficiency of mometasone furoate (MF) in treating inflammatory conditions is well established. However, its full potential is limited by its low solubility and dissolution rate. Addressing these issues, amorphous MF nanoparticles were developed using the Nanoedge technique. A Box–Behnken design was utilized to examine the effects of the stabilizer concentration and sonication time on the particle size, polydispersity index, zeta potential, and dissolution rate of the nanoparticles. The optimum amorphous nanoparticles (ONPs) were characterized by scanning electron microscopy, FT-IR spectroscopy, differential scanning calorimetry, and X-ray diffraction techniques. Moreover, the solubility, dissolution profile, and skin permeability of the ONPs were assessed. The concentration of stabilizers and sonication time were as crucial as the type of stabilizers in the nanoparticle formulation. ONPs displayed an amorphous halo pattern with a glass transition temperature of 175.4 °C. The solubility and dissolution rate of pristine MF drastically increased from 32.93 µg/ml and 1.09 × 10⁻² min⁻¹ up to 782.65 µg/ml and 53.7 × 10⁻² min⁻¹ in ONPs. Additionally, ONPs resulted in a quicker onset of action with improved skin permeability. In conclusion, it was determined that ONPs exhibit greater dissolution, solubility, and absorbability compared to pristine MF, indicating a promising future for amorphous nanoparticles in pharmaceutical applications.